A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
Therapeutic resistance remains a major obstacle in treating many cancers, particularly in advanced stages. It is likely that cytotoxic lymphocytes (CTLs) have the potential to eliminate therapy-resistant cancer cells. However, their effectiveness may be limited either by the immunosuppressive tumor...
Main Author: | Irina Kareva |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/18/10/2134 |
Similar Items
-
Metronomic Chemotherapy
by: Marina Elena Cazzaniga, et al.
Published: (2021-05-01) -
Metronomic chemotherapy regimens in oncology
by: M. Yu. Fedyanin, et al.
Published: (2016-04-01) -
Durable control of metastatic nasopharyngeal carcinoma with metronomic chemotherapy
by: Po-Hsiang Huang, et al.
Published: (2017-03-01) -
Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing
by: Doi Y, et al.
Published: (2016-10-01) -
Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non‐Hodgkin lymphoma
by: Ke Wu, et al.
Published: (2019-08-01)